ReviewJournal of fluorescence2025
Nanozymes: Classification and Analytical Applications - A Review.
Review in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A Biomimetic Copper-Caffeic Acid Nanozyme Activates Cuproptosis and Pyroptosis by Mimicking the Neutrophil Enzymatic Cascade.Advanced healthcare materials · 2026Article
- Nanozymatic platform for dual colorimetric and fluorimetric sensing of H₂O₂ and glucose using Ni-CoWO₄ nanoparticles.Scientific reports · 2026Article
- Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology.Micromachines · 2026Review
- A quenched electrochemiluminescence immunosensor based on luminol-Au NPs/Co-Fe-MOF and CuO@UiO-66-NHMikrochimica acta · 2026Article
- Advances in Immunological Methods for the Detection ofSensors (Basel, Switzerland) · 2026Review
- The Role and Mechanism of Nanozymes in Burn Wound Healing.International journal of nanomedicine · 2026Review
- Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.International journal of nanomedicine · 2026Review
- The Design Strategies and Applications of Engineered Nanoparticles for Traumatic Brain Injury.International journal of nanomedicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent discovery of a new class of nanomaterials called nanozymes, which have the action of enzymes and are thus of tremendous significance, has altered our understanding of these previously believed to be biologically inert nanomaterials. As a significant and exciting class of synthetic enzymes, nanozymes have distinct advantages over natural enzymes. They are less expensive, more stable, and easier to work with and store, making them a viable substitute. This practical advantage of nanozymes over natural enzymes reassures us about the potential of this new technology. Peroxidase-like nanozymes have been investigated for the purpose of creating adaptable biosensors via the use of molecularly imprinted polymers (MIPs) or particular bio recognition ligands, including enzymes, antibodies, and aptamers. This review delves into the distinctions between synthetic and natural enzymes, explaining their structures and analytical applications. It primarily focuses on carbon-based nanozymes, particularly those that contain both carbon and hydrogen, as well as metal-based nanozymes like Fe, Cu, and Au, along with their metal oxide (FeO, CuO), which have applications in many fields today. Analytical chemistry finds great use for nanozymes for sensing and other applications, particularly in comparison with other classical methods in terms of selectivity and sensitivity. Nanozymes, with their unique catalytic capabilities, have emerged as a crucial tool in the early diagnosis of COVID-19. Their application in nanozyme-based sensing and detection, particularly through colorimetric and fluorometric methods, has significantly advanced our ability to detect the virus at an early stage.
Indexed as
Identifiers
39271600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.